SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin shines on receiving EIR for Mandideep and Aurangabad units

27 May 2016 Evaluate

Lupin is currently trading at Rs. 1503.30, up by 33.20 points or 2.26% from its previous closing of Rs. 1470.10 on the BSE.

The scrip opened at Rs. 1475.00 and has touched a high and low of Rs. 1534.90 and Rs. 1475.00 respectively. So far 1,86,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1534.90 and Rs. 1443.75 respectively. The current market cap of the company is Rs. 67,816.00 crore.

The promoters holding in the company stood at 46.52% while Institutions and Non-Institutions held 42.27% and 11.22% respectively.

Pharma Major Lupin has received Establishment Inspection Reports (EIR) for its Mandideep and Aurangabad facilities wherein the US FDA has concluded that the inspections stand closed. The US FDA had conducted audits at Lupin’s Mandideep facility from 8th to 19th February, 2016 and its Aurangabad facility from 11th to 15th January, 2016. Earlier, the Company had taken appropriate steps to address the observations it had received from these audits. Having received the EIRs from the US FDA about the closure of these inspections, all observations stand addressed, and both these facilities are cGMP compliant.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×